Nothing Special   »   [go: up one dir, main page]

NL300390I1 - Anti-IL-12 antibodies, compositions, methods and uses. - Google Patents

Anti-IL-12 antibodies, compositions, methods and uses.

Info

Publication number
NL300390I1
NL300390I1 NL300390C NL300390C NL300390I1 NL 300390 I1 NL300390 I1 NL 300390I1 NL 300390 C NL300390 C NL 300390C NL 300390 C NL300390 C NL 300390C NL 300390 I1 NL300390 I1 NL 300390I1
Authority
NL
Netherlands
Prior art keywords
antibodies
compositions
methods
Prior art date
Application number
NL300390C
Other languages
Dutch (nl)
Other versions
NL300390I2 (en
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300390(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of NL300390I1 publication Critical patent/NL300390I1/en
Publication of NL300390I2 publication Critical patent/NL300390I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
NL300390C 2000-08-07 2009-05-13 Anti-IL-12 antibodies, compositions, methods and uses NL300390I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22335800P 2000-08-07 2000-08-07
US23682700P 2000-09-29 2000-09-29
US09/920,262 US6902734B2 (en) 2000-08-07 2001-08-01 Anti-IL-12 antibodies and compositions thereof
PCT/US2001/024720 WO2002012500A2 (en) 2000-08-07 2001-08-07 Anti-il-12 antibodies, compositions, methods and uses

Publications (2)

Publication Number Publication Date
NL300390I1 true NL300390I1 (en) 2009-07-01
NL300390I2 NL300390I2 (en) 2010-03-01

Family

ID=27397221

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300390C NL300390I2 (en) 2000-08-07 2009-05-13 Anti-IL-12 antibodies, compositions, methods and uses

Country Status (33)

Country Link
US (15) US6902734B2 (en)
EP (5) EP2305817B1 (en)
JP (4) JP4731094B2 (en)
KR (1) KR100823576B1 (en)
CN (2) CN101550190B (en)
AR (1) AR030134A1 (en)
AT (1) ATE431412T1 (en)
AU (2) AU2001281137B2 (en)
BR (1) BRPI0113109B8 (en)
CA (1) CA2418961C (en)
CL (1) CL2009000575A1 (en)
CY (7) CY1109149T1 (en)
DE (2) DE122009000025I1 (en)
DK (4) DK1309692T3 (en)
EA (1) EA006673B1 (en)
ES (4) ES2647220T3 (en)
FR (1) FR09C0021I2 (en)
HK (1) HK1135991A1 (en)
HR (1) HRP20030087B1 (en)
HU (1) HU228009B1 (en)
IL (1) IL154325A (en)
LT (6) LT3178934T (en)
LU (3) LU91584I2 (en)
ME (1) ME00326B (en)
MX (1) MXPA03001229A (en)
MY (1) MY133377A (en)
NL (1) NL300390I2 (en)
NO (3) NO330903B1 (en)
NZ (2) NZ535865A (en)
PT (4) PT3178934T (en)
RS (1) RS50477B (en)
SI (4) SI3178934T1 (en)
WO (1) WO2002012500A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
EP1494712A4 (en) * 2002-03-26 2006-06-14 Centocor Inc Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
DK1576011T3 (en) 2002-10-30 2009-11-30 Genentech Inc Inhibition of IL-17 production
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
ES2551682T3 (en) * 2002-11-08 2015-11-23 Ablynx N.V. Single domain antibodies directed against tumor necrosis factor-alpha and uses for them
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
BRPI0412885A (en) * 2003-07-18 2006-10-03 Amgen Inc polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
BRPI0507794A (en) * 2004-02-17 2007-07-17 Schering Corp methods of modulating il-23 activity, related reagents
AR051805A1 (en) * 2004-12-21 2007-02-07 Centocor Inc ANTI-IL-12 ANTIBODIES, EPITHOPES, COMPOSITIONS, METHODS AND USES
PT1839120E (en) * 2004-12-21 2014-01-03 Janssen Biotech Inc Anti-il-12 antibody based vectors, host cells, and methods of production and uses
EP1871803B1 (en) 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
CN103172738A (en) * 2005-06-30 2013-06-26 Abbvie公司 IL-12/P40 binding proteins
JP2007172129A (en) * 2005-12-20 2007-07-05 Sony Corp Nonvolatile memory access control device and nonvolatile memory control system
AU2007266306A1 (en) * 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated IL-12 molecule or chimeric molecules thereof
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
RU2475265C2 (en) 2007-01-16 2013-02-20 Эбботт Лэборетриз Methods of treating psoriasis
KR20100014674A (en) * 2007-03-29 2010-02-10 아보트 러보러터리즈 Crystalline anti-human il-12 antibodies
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
JP2011504740A (en) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． Amino acid sequence directed to heterodimeric cytokines and / or their receptors, and polypeptides containing the same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8178092B2 (en) * 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
KR101508086B1 (en) * 2008-05-05 2015-04-07 노비뮨 에스 에이 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
SG10201702951RA (en) * 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
RU2011120178A (en) * 2008-10-20 2012-11-27 Эбботт Лэборетриз ANTIBODIES THAT CONTACT IL-12 AND METHODS FOR CLEANING THEM
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
BRPI1014544B8 (en) 2009-05-05 2021-05-25 Novimmune Sa isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
KR20120112384A (en) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 Methods for treating psoriasis
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012045075A1 (en) 2010-10-01 2012-04-05 Jason Schrum Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TW201309330A (en) * 2011-01-28 2013-03-01 Abbott Lab Compositions containing glycosylated antibodies and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
SG10201604896TA (en) 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
ES2749200T3 (en) * 2012-05-10 2020-03-19 Bioatla Llc Multispecific monoclonal antibodies
ES2729603T3 (en) 2012-06-27 2019-11-05 Merck Sharp & Dohme IL-23 anti-human crystalline antibodies
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
WO2016172359A2 (en) * 2015-04-24 2016-10-27 The Regents Of The University Of California Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
JP7030689B2 (en) * 2015-10-23 2022-03-07 ファイザー インコーポレイティッド Anti-IL-2 antibody and its composition and use
EA201892190A1 (en) * 2016-03-29 2019-04-30 Янссен Байотек, Инк. TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
US20200347126A1 (en) 2016-08-03 2020-11-05 Fyb 202 Project Gmbh Production of Biosimilar Ustekinumab In CHO Cells
CA3044244A1 (en) * 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il23 specific antibody
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045475A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
MA47362A (en) 2017-01-30 2019-12-04 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
KR20190115042A (en) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Ankylosing Spondylitis
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
TW201922780A (en) * 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
TR201808283A2 (en) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S WATER PHARMACEUTICAL ETHENERSEPT COMPOSITION
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN113395979A (en) 2018-11-20 2021-09-14 詹森生物科技公司 Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies
JP2022518208A (en) 2019-01-15 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Juvenile Idiopathic Arthritis
US20220064278A1 (en) 2019-01-23 2022-03-03 Janssen Biotech, Inc. Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
JP2022524860A (en) 2019-03-14 2022-05-10 ヤンセン バイオテツク，インコーポレーテツド Methods for Producing Anti-TNF Antibody Compositions
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
EA202192459A1 (en) * 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
AU2020288404A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
MX2022001305A (en) * 2019-07-30 2022-05-06 Akeso Biopharma Inc Anti-human p40 protein domain antibody and use thereof.
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2020409124A1 (en) 2019-12-20 2022-06-30 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2022024065A1 (en) * 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240034218A (en) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 Manufacturing Methods for Producing Anti-TNF Antibody Compositions
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122464A (en) 1872-01-02 Improvement in cheese-hoops
US941234A (en) 1909-02-25 1909-11-23 Frank De Clercq Syrup-percolator.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (en) 1976-10-23 1978-07-21 Choay Sa PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3590766C2 (en) 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
SE448277B (en) 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8517895D0 (en) 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (en) 1986-01-15 1987-07-16 Ant Nachrichtentech METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (en) 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (en) 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
US5075236A (en) 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
ATE108068T1 (en) 1987-09-23 1994-07-15 Bristol Myers Squibb Co ANTIBODY HETEROCONJUGATES FOR KILLING HIV-INFECTED CELLS.
JP2980626B2 (en) 1988-01-11 1999-11-22 ゾーマ・コーポレーション Novel plasmid vector containing pectate lyase signal sequence
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
CA2002607C (en) 1988-11-10 2004-01-27 Gordon G. Wong Natural killer stimulatory factor
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (en) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh METHOD FOR PRODUCING BISPECIFIC ANTIBODIES
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
WO1991005058A1 (en) 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
DK0790308T3 (en) 1989-12-22 2007-10-08 Hoffmann La Roche Cytoxic lymphocyte maturation factor 35kD subunit and monoclonal antibodies directed thereto
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
TW212184B (en) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018980A1 (en) 1990-06-01 1991-12-12 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
KR0149181B1 (en) 1990-06-29 1998-08-17 데이비드 알, 맥지 Melanin production by transformed microorganisms
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
DK0575545T3 (en) 1991-03-15 2003-09-15 Amgen Inc Pegylation of polypeptides
ATE269401T1 (en) 1991-04-10 2004-07-15 Scripps Research Inst LIBRARIES OF HETERODIMERIC RECEPTORS USING PHAGEMIDS
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0592540B1 (en) 1991-07-02 2000-01-26 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (en) 1992-03-10 1993-09-16 Goldwell Ag MEDIUM FOR BLONDING HUMAN HAIR AND METHOD FOR THE PRODUCTION THEREOF
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
KR0177265B1 (en) 1992-10-19 1999-04-01 미첼 알. 우드베리 Dry powder inhaler
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
ES2124870T3 (en) 1993-01-19 1999-02-16 Glaxo Group Ltd AEROSOL DISTRIBUTOR AND MANUFACTURING PROCEDURE.
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP3824633B2 (en) 1993-02-12 2006-09-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ Regulatory transcription of target genes and other biological consequences
EP0614989A1 (en) 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08509612A (en) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
KR950701934A (en) * 1993-04-30 1995-05-17 아사이 잇뻬이 PURIFICATION METHOD FOR HYDROPHOBIC POLYPEPTIDE
DE4315127A1 (en) 1993-05-07 1994-11-10 Behringwerke Ag Medicinal product containing the p40 subunit of interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (en) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
SE9304060D0 (en) 1993-12-06 1993-12-06 Bioinvent Int Ab Methods to select specific bacteriophages
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU692239B2 (en) 1994-03-07 1998-06-04 Medarex, Inc. Bispecific molecules having clinical utilities
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
AU695273B2 (en) 1994-04-22 1998-08-13 Corixa Corporation Compounds and methods for the stimulation and enhancement ofprotective immune responses and IL-12 production
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
CN1213974A (en) 1996-01-03 1999-04-14 葛兰素集团有限公司 Inhalation device
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (en) 1996-06-19 1999-08-19 Hatz Motoren Cold start device
EP0826695B1 (en) 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Destruction of contaminating tumor cells in stem cell transplants by use of bispecific antibodies
PT1500329E (en) 1996-12-03 2012-06-18 Amgen Fremont Inc Human antibodies that specifically bind human tnf alpha
AU6150498A (en) 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JP4481489B2 (en) 1998-01-23 2010-06-16 エフ．ホフマン−ラ ロシュ アーゲー Antibody against human IL-12
US6410824B1 (en) 1998-12-09 2002-06-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
KR20140094647A (en) * 1999-03-25 2014-07-30 아비에 도이치란트 게엠베하 운트 콤파니 카게 Human antibodies that bind human IL-12 and methods for producing
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2003247411A1 (en) 2002-05-23 2003-12-12 Cognis Corporation NON-REVERTIBLE Beta-OXIDATION BLOCKED CANDIDA TROPICALIS
DE102007030072A1 (en) 2007-06-29 2009-01-02 BSH Bosch und Siemens Hausgeräte GmbH Electric drive device for a water-conducting household appliance
JP5470817B2 (en) 2008-03-10 2014-04-16 日産自動車株式会社 Battery electrode, battery using the same, and manufacturing method thereof
JP5155355B2 (en) 2010-04-07 2013-03-06 レノボ・シンガポール・プライベート・リミテッド Wireless terminal device capable of autonomous load adjustment of wireless base station
US9619256B1 (en) 2012-06-27 2017-04-11 EMC IP Holding Company LLC Multi site and multi tenancy
JP6136279B2 (en) 2013-01-15 2017-05-31 株式会社ジェイテクト Rolling bearing device
TWI503850B (en) 2013-03-22 2015-10-11 Polytronics Technology Corp Over-current protection device
TWI510996B (en) 2013-10-03 2015-12-01 Acer Inc Methods for controlling a touch panel and portable computers using the same
US9205258B2 (en) 2013-11-04 2015-12-08 ElectroCore, LLC Nerve stimulator system
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
ES2747573T3 (en) 2020-03-10
ES2624502T3 (en) 2017-07-14
ATE431412T1 (en) 2009-05-15
LUC00145I2 (en) 2021-08-13
US7887807B2 (en) 2011-02-15
CY1118901T1 (en) 2018-02-14
YU9303A (en) 2006-05-25
US20110082190A1 (en) 2011-04-07
LU91584I9 (en) 2019-01-03
JP2004527212A (en) 2004-09-09
US20180334500A1 (en) 2018-11-22
EA200300137A1 (en) 2003-08-28
CY2018010I2 (en) 2018-09-05
EP2090657A3 (en) 2011-12-28
US7279157B2 (en) 2007-10-09
US20080090290A1 (en) 2008-04-17
LTPA2018007I1 (en) 2018-04-10
US9409984B2 (en) 2016-08-09
RS50477B (en) 2010-03-02
HU228009B1 (en) 2012-08-28
US20130064760A1 (en) 2013-03-14
JP2015061835A (en) 2015-04-02
NO2011023I2 (en) 2011-10-04
CA2418961C (en) 2009-11-03
EP1309692B1 (en) 2009-05-13
NO330903B1 (en) 2011-08-15
WO2002012500A3 (en) 2003-01-03
US8703141B2 (en) 2014-04-22
US20120063998A1 (en) 2012-03-15
NO20030614D0 (en) 2003-02-07
DK2090657T3 (en) 2017-06-06
US20050214293A1 (en) 2005-09-29
US7166285B2 (en) 2007-01-23
LTC2305817I2 (en) 2021-04-26
EA006673B1 (en) 2006-02-24
FR09C0021I2 (en) 2010-06-11
LUC00066I2 (en) 2018-05-25
NO20030614L (en) 2003-04-02
PT3178934T (en) 2019-10-14
US20030124123A1 (en) 2003-07-03
MXPA03001229A (en) 2003-10-15
CN101550190A (en) 2009-10-07
KR20030034133A (en) 2003-05-01
SI2090657T1 (en) 2017-06-30
EP2090657A2 (en) 2009-08-19
PT1309692E (en) 2009-05-21
JP6076303B2 (en) 2017-02-08
SI1309692T1 (en) 2009-08-31
US10259867B2 (en) 2019-04-16
SI3178934T1 (en) 2019-10-30
CY1109149T1 (en) 2012-01-25
LT2090657T (en) 2017-07-25
US7560247B2 (en) 2009-07-14
NO2011023I1 (en) 2011-10-17
CN1468309A (en) 2004-01-14
LTC1309692I2 (en) 2020-06-25
CA2418961A1 (en) 2002-02-14
US20050196838A1 (en) 2005-09-08
MY133377A (en) 2007-11-30
BRPI0113109B8 (en) 2021-05-25
CY2020003I1 (en) 2020-05-29
JP2012025779A (en) 2012-02-09
LUC00066I1 (en) 2018-03-23
DE122009000025I1 (en) 2009-09-17
US20090274707A1 (en) 2009-11-05
DE60138711D1 (en) 2009-06-25
NO2020005I1 (en) 2020-03-11
US10519231B2 (en) 2019-12-31
US6902734B2 (en) 2005-06-07
IL154325A0 (en) 2003-09-17
IL154325A (en) 2010-12-30
US20140178295A1 (en) 2014-06-26
EP2305817A3 (en) 2011-12-28
CN101550190B (en) 2016-04-13
CL2009000575A1 (en) 2009-07-17
EP3597752A1 (en) 2020-01-22
JP4731094B2 (en) 2011-07-20
AU8113701A (en) 2002-02-18
PL360258A1 (en) 2004-09-06
US20050002937A1 (en) 2005-01-06
BRPI0113109B1 (en) 2017-02-07
CY1119650T1 (en) 2018-04-04
LT2305817T (en) 2017-11-27
FR09C0021I1 (en) 2009-09-25
US8329171B2 (en) 2012-12-11
LTPA2009002I1 (en) 2020-03-25
EP3178934A1 (en) 2017-06-14
PT2090657T (en) 2017-05-03
US20200062841A1 (en) 2020-02-27
EP1309692A2 (en) 2003-05-14
US20190248884A1 (en) 2019-08-15
US20170029496A1 (en) 2017-02-02
US9676848B2 (en) 2017-06-13
DK1309692T3 (en) 2009-06-15
US8084233B2 (en) 2011-12-27
KR100823576B1 (en) 2008-04-21
LTPA2020001I1 (en) 2020-02-10
US20050112127A1 (en) 2005-05-26
ES2647220T3 (en) 2017-12-20
HK1135991A1 (en) 2010-06-18
CY2009007I1 (en) 2012-01-25
LT3178934T (en) 2019-09-25
WO2002012500A2 (en) 2002-02-14
DK2305817T3 (en) 2017-12-04
MEP44408A (en) 2011-02-10
EP3178934B1 (en) 2019-07-24
HRP20030087B1 (en) 2012-07-31
CY2020003I2 (en) 2020-05-29
CY1122505T1 (en) 2020-05-29
NZ535865A (en) 2007-01-26
CY2018010I1 (en) 2018-09-05
EP2305817A2 (en) 2011-04-06
HRP20030087A2 (en) 2005-10-31
HUP0302378A2 (en) 2003-10-28
EP2090657B1 (en) 2017-03-01
SI2305817T1 (en) 2018-02-28
AR030134A1 (en) 2003-08-13
AU2001281137B2 (en) 2007-03-15
US11078267B2 (en) 2021-08-03
BR0113109A (en) 2004-02-03
EP2305817B1 (en) 2017-09-27
ES2323760T3 (en) 2009-07-24
ME00326B (en) 2011-05-10
PT2305817T (en) 2017-10-26
JP2011173884A (en) 2011-09-08
LU91584I2 (en) 2009-09-10
NL300390I2 (en) 2010-03-01
NZ524145A (en) 2004-11-26
CY2009007I2 (en) 2012-01-25
US7063964B2 (en) 2006-06-20
DK3178934T3 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
NL300390I1 (en) Anti-IL-12 antibodies, compositions, methods and uses.
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
HK1083509A1 (en) Anti-il-6 antibodies, compositions, methods and uses
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
EP1578930A4 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
MXPA03007693A (en) Composition.
IL161235A0 (en) Fsh composition, its preparation and use
EP1711527A4 (en) Hla-dr-specific antibodies, compositions and methods
EG23378A (en) Composition.
EP1539792A4 (en) Cngh0005 polypeptides, antibodies, compositions, methods and uses
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2003237332A8 (en) Anti-relp fusion antibodies, compositions, methods and uses
MXPA01000464A (en) Composition.
MXPA03008077A (en) Composition.
EP1501870A4 (en) Rsv proteins, antibodies, compositions, methods and uses
GB0128964D0 (en) Assays, methods and means
GB0010191D0 (en) Assays, methods and means
GB0118952D0 (en) Assays,methods and means
GB0123388D0 (en) Assays,methods and means
GB0111574D0 (en) Assays,methods and means